Maurer, Britta <br/><br/>
Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.  [electronic resource] 

 -  Annals of the rheumatic diseases  Dec 2013 
 - 2039-46 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/annrheumdis-2013-203729  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Animals<br/>Benzamides--therapeutic use<br/>Biopsy<br/>Bleomycin<br/>Disease Models, Animal<br/>Drug Evaluation, Preclinical--methods<br/>Female<br/>Fibrosis<br/>Fos-Related Antigen-2--genetics<br/>Humans<br/>Imatinib Mesylate<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Transgenic<br/>Middle Aged<br/>Molecular Targeted Therapy--methods<br/>Piperazines--therapeutic use<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein Serine-Threonine Kinases--genetics<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-abl--metabolism<br/>Proto-Oncogene Proteins c-sis--metabolism<br/>Pyrimidines--therapeutic use<br/>Scleroderma, Systemic--drug therapy<br/>Skin--metabolism<br/>Treatment Outcome